secwatch / observer
8-K filed October 1, 2024, 7:59 PM ET ticker VRCA CIK 0001660334
other material confidence high sentiment negative materiality 0.60

Verrica Pharmaceuticals Inc. (VRCA): restructuring charge — Verrica cuts 47 jobs, expects $1.0M restructuring charge

Verrica Pharmaceuticals Inc.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

Verrica Pharmaceuticals Inc. announced a restructuring with charges of approximately $1.0 million, including a one-time charge totaling approximately $0.7 million in connection with one-time employee termination costs, including se (reduction of its workforce by 47 employees).

Type
restructuring
Charge
approximately $1.0 million, including a one-time charge totaling approximately $0.7 million in connection with one-time employee termination costs, including se
Headcount
reduction of its workforce by 47 employees
Exact text from the filing
On October 1, 2024, Verrica Pharmaceuticals Inc. (the “Company”) announced a reduction of its workforce by 47 employees, which the Company expects to be substantially completed by October 1, 2024. The Board of Directors of the Company approved these actions on September 23, 2024 in order to streamline operations, reduce costs, and preserve capital. As a result, the Company expects to incur total expenses of approximately $1.0 million, including a one-time charge totaling approximately $0.7 million in connection with one-time employee termination costs, including severance and other benefits, and an estimated deemed loss on vehicle sales of $0.3 million.
View on SEC.gov

6 restructurings & charges filed in the last 30 days. Browse all restructurings & charges →

Verrica Pharmaceuticals Inc. filing history →

Source: SEC EDGAR
accession 0001193125-24-230240
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.